Cashu | News | FL

HomeWatchlistNewsSignalsPicks

DJI

-0.61%

SPX

-0.67%

IXIC

-1.00%

FTSE

-0.24%

N225

+0.47%

AXJO

+0.15%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest Foot Locker News

Cramer's week ahead: Earnings from Nvidia, Dell, Costco and Salesforce

Feature Image for interests on Business, Consumer Cyclical, Consumer Defensive, Investment Strategy from cnbc.com

PeproMene Bio, Inc. und das Institute for Follicular Lymphoma Innovation (IFLI) geben bekannt, dass der erste Patient mit follikulrem Lymphom (FL), der mit BAFF-R zielgerichteten CAR-T-Zellen (PMB-CT01) behandelt wurde, ein vollstndiges Ansprechen erreicht hat

Feature Image for interests on Biotechnology, Clinical Trials & Medical Discoveries, Consumer Cyclical, Health Care & Hospitals from prnewswire.com

How To Earn $500 A Month From Dick's Sporting Goods Stock Ahead Of Q1 Earnings

Feature Image for interests on $500 Dividend, Benzinga, Consumer Cyclical, Dividend Yield from benzinga.com

Dealmaking rebounds after Trump's tariffs cut off a budding M&A boom

Feature Image for interests on Breaking News: Markets, Communication Services, Consumer Cyclical, Consumer Defensive from cnbc.com

Nike will raise prices on a wide range of products as soon as this week

Feature Image for interests on Apparel Retail, Breaking News: Business, Business, Commerce from cnbc.com

Here are 6 portfolio stocks to buy right here, right now

Feature Image for interests on Basic Materials, Breaking News: Business, Breaking News: Markets, Communication Services from cnbc.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

Feature Image for interests on Biotechnology, Clinical Trials & Medical Discoveries, Consumer Cyclical, Health Care & Hospitals from prnewswire.com

What's Next For Foot Locker? Analyst Says Dick's Deal Is Timely

Feature Image for interests on Analyst Ratings, Benzinga, Briefs, Consumer Cyclical from benzinga.com

Wall Street Poised To Open Higher After S&P 500's 4-Day Run: 'Sounds Like Powell Is Expecting More Frequent Bouts Of Stagflation,' Cautions Expert (CORRECTED)

Feature Image for interests on Amat, Amzn, Benzinga, Brc from benzinga.com

Wall Street Poised To Open Higher After S&P 500's 4-Day Run: 'Sounds Like Powell Is Expecting More Frequent Bouts Of Stagflation,' Cautions Expert

Feature Image for interests on Amat, Amzn, Benzinga, Brc from benzinga.com

Stocks

Consumer Discretionary

fl

Foot Locker

FL

-0.16 (-0.67%)

23.71

USD

At close at May 23, 20:37 UTC

Latest Cashu News

Foot Locker Stock: Promising Advances in Lymphoma Treatment by PeproMene Bio, Inc.

Foot Locker Faces Challenges Amid Innovations in Follicular Lymphoma Treatment and Retail Pricing Dynamics

Foot Locker's Strategic Adaptation Amid Retail Changes: Analyst Upgrades Price Target